Scarica l'app Stockscreener
18.84
1.62%
-0.31
Dopo l'orario di chiusura:
18.80
-0.04
-0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.15
Aprire:
$18.56
Volume 24 ore:
3.00M
Relative Volume:
1.79
Capitalizzazione di mercato:
$1.93B
Reddito:
$70.85M
Utile/perdita netta:
$-324.22M
Rapporto P/E:
-4.9494
EPS:
-3.8065
Flusso di cassa netto:
$-277.36M
1 W Prestazione:
-33.19%
1M Prestazione:
-37.72%
6M Prestazione:
-11.22%
1 anno Prestazione:
+44.15%
Intervallo 1D:
$18.44
$19.25
Intervallo di 1 settimana:
$16.97
$28.18
Portata 52W:
$9.90
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.84 | 1.93B | 70.85M | -324.22M | -277.36M | -3.8065 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Reiterato | Wedbush | Outperform |
| 2025-12-03 | Iniziato | William Blair | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Earnings Report: Should I hold or sell Viridian Therapeutics Inc nowForecast Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $48 - moomoo.com
VRDN Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
EBIT per share of Viridian Therapeutics, Inc. – LSE:0K1R - TradingView
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart DataWhat's Changed - Sahm
Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal? - Stocktwits
Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history - Yahoo Finance UK
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-04-02 - Seeking Alpha
Transcript : Viridian Therapeutics, Inc.Special Call - marketscreener.com
Are Viridian Therapeutics' (VRDN) REVEAL-1 Results Enough To Redefine Its TED Competitive Position? - Yahoo Finance
Viridian Therapeutics (VRDN) Target Price Lowered by Evercore IS - GuruFocus
What is HC Wainwright's Estimate for VRDN FY2027 Earnings? - MarketBeat
Discipline and Rules-Based Execution in VRDN Response - Stock Traders Daily
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock? - qz.com
J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics (VRDN) Jumps 5.6%: Does the Stock Have More Room to Grow? - Bitget
Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly - Seeking Alpha
HC Wainwright Has Negative Outlook for VRDN Q1 Earnings - MarketBeat
Viridian Therapeutics, Inc. $VRDN Stock Position Decreased by JPMorgan Chase & Co. - MarketBeat
Aug Decliners: Will Viridian Therapeutics Inc benefit from geopolitical trends2026 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
Viridian releases phase 3 topline data on elegrobart for TED - Eyes On Eyecare
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $36.00 at The Goldman Sachs Group - MarketBeat
Viridian Therapeutics (VRDN) Analyst Ratings Update: Wells Fargo Lowers Price Target | VRDN Stock News - GuruFocus
VRDN: Wedbush Lowers Price Target While Maintaining Outperform R - GuruFocus
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $20.00 at Wells Fargo & Company - MarketBeat
Viridian shares plummet on elegrobart trial results - thepharmaletter.com
VRDN: Analyst Maintains 'Buy' Rating, Lowers Price Target to $22 - GuruFocus
HC Wainwright Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $22.00 - MarketBeat
H.C. Wainwright cuts Viridian Therapeutic price target on TED trial results - Investing.com Canada
Wolfe Research cuts Viridian Therapeutic price target on trial outlook - Investing.com
Wolfe Research cuts Viridian Therapeutic price target on trial outlook By Investing.com - Investing.com Canada
Viridian reports positive phase 3 trial results for TED drug By Investing.com - Investing.com Australia
Trade Recap: Can Viridian Therapeutics Inc be the next market leaderBuy Signal & Reliable Breakout Forecasts - baoquankhu1.vn
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease - BioSpace
Viridian Therapeutics price target lowered to $32 from $42 at Needham - TipRanks
Published on: 2026-03-31 08:41:04 - baoquankhu1.vn
Viridian Therapeutics price target lowered to $37 from $44 at Wedbush - TipRanks
Viridian Therapeutics (VRDN) Reports Success in Phase 3 Trial fo - GuruFocus
Viridian Therapeutics Plummets 32% on Mixed Trial Results Despite Record Trading Volume - Bitget
Viridian Therapeutics (VRDN) Shares Plummet Over 33% - GuruFocus
VRDN: Needham Lowers Price Target but Maintains Buy Rating | VRD - GuruFocus
Viridian Therapeutics (VRDN) Shares Plummet After Trial Results - GuruFocus
Viridian Therapeutics price target lowered to $29 from $45 at Jefferies - TipRanks
Viridian Therapeutics (VRDN) Experiences Significant Stock Decli - GuruFocus
Viridian Therapeutics (VRDN) Faces Mixed Data, Shares Fall - GuruFocus
Why This Amgen Rival Just Plummeted By A Third - Investor's Business Daily
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease (VRDN:NASDAQ) - Seeking Alpha
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):